UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER ~~PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934~~

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File ~~No.~~Number: 001-42453

~~PARK~~Park HAHa ~~BIOLOGICAL~~Biological ~~TECHNOLOGY~~Technology COCo., ~~LTD~~Ltd.

~~(Translation~~901, ofBuilding ~~registrant’s~~C, ~~name~~Phase 2 ~~into English)~~

~~901, Building C Phase 2,~~ Wuxi International Life Science Innovation Campus 196 Jinghui East Road ~~Xinwu District, Wuxi, Jiangsu Province People’s Republic of China 214000~~

~~(Address~~Xinwu ofDistrict, ~~principal~~Wuxi, ~~executive~~Jiangsu ~~office)~~Province People’s Republic of China 214000

~~Indicate~~+86 by400 ~~check~~012 ~~mark~~7562 ~~whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F~~

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

On March 616, 2026, Ms. Li Wang tendered her resignation as a director of Park Ha Biological Technology Co., Ltd. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that because the Company’s Class A ordinary shares had a closing bid price at or above $1.00 per share for 10 consecutive business days, ~~from~~effective ~~February 20 through~~ March 516, 2026,. ~~the~~Ms. ~~Company~~Li ~~had~~Wang’s ~~regained~~resignation was ~~compliance~~not ~~with~~a ~~the~~result ~~minimum bid price requirement~~ of ~~$1.00 per~~any ~~share~~disagreement ~~for~~with ~~continued listing on~~ the ~~Nasdaq~~Company’s ~~Capital Market~~operations, aspolicies ~~set~~or ~~forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed~~procedures.

~~SIGNATURE~~SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 6, 2026

	Park Ha Biological Technology Co., Ltd.

Date: March 16, 2026	By:	/s/ Xiaoqiu Zhang
	Name:	Xiaoqiu Zhang
	Title:	Chief Executive Officer, Chairperson of the Board of Directors

Park Ha Biological Technology Co., Ltd. By: /s/ Xiaoqiu Zhang Name: Xiaoqiu Zhang Title: Chief Executive Officer and Chairperson of the Board

Filing Compare · Park Ha Biological Technology Co., Ltd.